DUBLIN–(BUSINESS WIRE)–The “Biologics Contract Development and Manufacturing Organization Market Forecast to 2033” has been added to ResearchAndMarkets.com’s offering.
The global biologics contract development and manufacturing organization (CDMO) market, valued at USD 19.22 billion in 2024, is projected to grow at a compound annual growth rate of 9.21%, reaching USD 42.32 billion by 2033. This expansion is fueled by the increasing demand for targeted therapies to address chronic and rare diseases within an aging global population.
Pharmaceutical and biopharmaceutical companies are leveraging CDMO services to enhance their capacities and access specialized technologies. This trend is further supported by rising investments and a surge in venture capital, strategic collaborations, mergers, and acquisitions across the industry. Major pharmaceutical corporations are focusing on acquisitions to diversify their therapeutic portfolios and bolster biologics pipelines.
The shifting focus of regulatory bodies such as the U.S. FDA and EMA on refining approval pathways for biosimilars, cell therapies, and gene-based treatments is fostering innovation while ensuring patient safety. New harmonized standards are streamlining submissions, reducing delays, and driving market expansion through faster approvals of novel therapies.
Global Biologics CDMO Market Segmentation
This report delivers revenue growth forecasts at global, regional, and country levels from 2021 to 2033 across several sub-segments, divided by product, service, source, workflow, therapeutic area, and region.
Product Outlook (Revenue, USD Million, 2021-2033)
- Monoclonal antibodies (mAbs)
- Recombinant proteins & enzymes
- Vaccines
- Cell & Gene Therapies
- Nucleic acid Therapeutics
- Others
Service Outlook (Revenue, USD Million, 2021-2033)
- Contract Development
- Contract Manufacturing
- Packaging and Labelling
- Regulatory Affairs
- Logistics & Storage
- Others
Source Outlook (Revenue, USD Million, 2021-2033)
- Mammalian
- Microbial
Workflow Outlook (Revenue, USD Million, 2021-2033)
- Clinical
- Commercial
Therapeutic Area Outlook (Revenue, USD Million, 2021-2033)
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Neurological Diseases
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Pharmaceutical Companies
- Biotechnology Companies
- Academic and Research Institutions
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Why You Should Buy This Report
- Access comprehensive market analysis across major regions and segments.
- Explore the competitive landscape and key player presence.
- Identify pivotal trends and drivers shaping the market’s future.
- Leverage actionable recommendations to discover new revenue streams.
Report Deliverables
- Market intelligence to guide effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Insight into growth opportunities and trends
- Revenue forecasts for market assessment
- Analysis of competition strategies and market shares
- Product innovation listings to stay competitive
Key Attributes
| Report Attribute | Details |
| No. of Pages | 120 |
| Forecast Period | 2024 – 2033 |
| Estimated Market Value (USD) in 2024 | $19.22 Billion |
| Forecasted Market Value (USD) by 2033 | $42.32 Billion |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | Global |
The companies profiled in this Biologics Contract Development and Manufacturing Organization market report include:
- Lonza Group
- Catalent Pharma Solutions
- Samsung Biologics
- WuXi Biologics / WuXi AppTec
- Thermo Fisher Scientific
- Fujifilm Diosynth Biotechnologies
- Boehringer Ingelheim (Biopharma CDMO)
- Rentschler Biopharma SE
- AGC Biologics
- Charles River Laboratories
- Siegfried Holding
- Sandoz
- GenScript Biologics
- Vetter Pharma
- IDT Biologika
For more information about this report visit https://www.researchandmarkets.com/r/idjtme
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900